CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 7. Resistance of dominant active STAT3 transfectants to the EGFR autocrine axis. A, representative MTT assay demonstrating growth stimulation of vector control transfectants relative to untreated control cells, compared with STAT3-C-transfected cells treated with exogenous EGFR ligand (EGF, 30 ng/ml). The experiment was repeated three times with 3 wells/condition for each experiment. B, representative MTT assay demonstrating relative growth inhibition of control-transfected cells compared with STAT3-C transfectants treated with an EGFR-specific tyrosine kinase inhibitor at either of two doses ({square}, 100 nM PD153035; , 1000 nM PD153035).





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation